Compare Amphastar Pharmaceuticals Inc (AMPH) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Jones Lang LaSalle Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Jones Lang LaSalle Inc trades at $362.41 (market cap $16.44B). The key difference: Jones Lang LaSalle Inc is far larger — about 19× Amphastar Pharmaceuticals Inc's market cap, and Jones Lang LaSalle Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | JLL | |
|---|---|---|
Market Cap | $863.95M | $16.44B |
Sector | Health | Real Estate |
52-Week High | $30.81 | $373.24 |
52-Week Low | $16.87 | $275.79 |
Enterprise Value | $1.26B | $19.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
JLL trades at $362.38, down 0.36% on the day, near its 52-week high. The stock shows a bullish technical trend with consistent earnings beats in recent quarters. Revenue grew to $26.12B in 2025, with net income reaching $792.10M, and analysts project further growth in 2026. Positive sentiment is driven by strong Q2 2026 results and AI-related real estate demand highlighted in recent company research.
Outlook remains positive with a consensus price target of $391.50, though risks include market volatility and execution challenges in capital markets. The stock offers growth potential from expanding profit margins and strategic positioning in AI-impacted real estate sectors, balanced by economic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
